Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (" Defence " or the " Company "), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, announces that it offers new unsecured convertible debentures (the "... Read More

Vancouver, British Columbia--(Newsfile Corp. - November 13, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (" Defence " or the " Company "), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that Dr. Svetlana Selivanova has joined the... Read More

Vancouver, British Columbia--(Newsfile Corp. - November 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (" Defence " or the " Company "), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that it has received a 30-day extension... Read More

Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (" Defence " or the " Company "), a Canadian biopharmaceutical company developing radiopharmaceuticals and novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the closing of the 1 st tranche of its previously announced non-brokered private placement (the "... Read More

Vancouver, British Columbia--(Newsfile Corp. - September 27, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and novel immune-oncology vaccines and drug delivery technologies, is pleased to give a corporate update and to announce a financing. The Company wishes to announce that Mr. Sebastien Plouffe,... Read More

Vancouver, British Columbia--(Newsfile Corp. - August 30, 2024) - Defence Therapeutics Inc . (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (" Defence " or the " Company "), announces that Kwin Grauer has been appointed interim Chief Executive Officer replacing Sébastien Plouffe as President and Chief Executive Officer. This change comes as the Company moves from the preclinical stage toward a clinical stage. Mr. Grauer joined the... Read More

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce a project consisting of investigating the potential benefit of using the Accum ® technology to increase the half-life and efficacity of... Read More

Vancouver, British Columbia--(Newsfile Corp. - August 13, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to give an update on its Orano Support SAS partnership in the radiopharmaceuticals field , on behalf of Orano SAS ("Orano"), a world-renowned... Read More

Vancouver, British Columbia--(Newsfile Corp. - July 24, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its Canadian Nuclear Research Initiative Health ("CNRI-H") Program application was retained and approved by the Canadian Nuclear... Read More

Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that it received a No Objection Letter ("NOL") from Health Canada for its Clinical Trial Study number ACCUM-002-01 entitles "A Phase I... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 28, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce that Defence's Accum-002 TM ("AccuTOX ® ") has different mode of actions: AccuTOX ® is working as a tumor killing molecule and as an... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation ARM-X... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to share the interview of Dr. Moutih Rafei, Defence's Chief Scientific Officer, with Ellis Martin on Money Talk Radio. To Listen to the Interview,... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce its participation to the Society of Nuclear and Molecular Imaging ("SNMMI") annual meeting on June 11, 2024 at the Metro Toronto... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce the publication of a peer-reviewed study on the anticancer properties of its unconjugated AccuTOX®, one of Defence's lead products... Read More

Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (" Defence " or the " Company "), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the issuance of several new patents, as well as new allowances of patent applications belonging to different Patent Families in... Read More

Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), (" Defence " or the " Company "), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the successful completion of a pre-clinical vaccination trial using its ARM-002 TM vaccine against pancreatic cancer. The vaccine... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 23, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (" Defence " or the " Company "), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that its second-generation ARM TM anti-cancer vaccine using AccuTOX ® , called ARM-002 TM , is therapeutically effective against... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (" Defence " or the " Company "), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that FMS Consult GmbH ("FMS"), a European corporate financing consulting firm, was commissioned by Defence to execute on a... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 5, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (" Defence " or the " Company "), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces an amendment to the terms of 1,497,780 Class A Common share purchase warrants (the " Warrants ") originally issued as part of a private placement closed on November... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (" Defence " or the " Company "), a Canadian biotechnology company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the successful testing of a second-generation anti-cancer vaccine, called ARM-002 TM , using its lead anti-cancer molecule AccuTOX ®... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 22, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), (" Defence " or the " Company "), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces the closing of the 2 nd tranche of its previously announced non-brokered private placement (the " Offering ") of units of the Company (the " Units ") at a price... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (" Defence " or the " Company "), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the granting of US patent no. 11,890,350 ('350) by the United States Patent and Trademark Office (USPTO), broadly covering its... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (" Defence " or the " Company "), one of the leading Canadian biotechnology companies working in the field of immune-oncology, is pleased to announce the publication of a peer-reviewed study on the anticancer properties of its dual Accum ® -E7 vaccine, one of Defence's experimental product... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (" Defence " or the " Company "), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces the closing of the 1 st tranche of its previously announced non-brokered private placement (the " Offering ") of units of the Company (the " Units ") at a price... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (" Defence " or the " Company "), one of the leading Canadian biotechnology companies working in the field of immune-oncology announces, further to its news release on January 12, 2024, an amendment on the financing. The Company will now be conducting a non-brokered private placement of up to... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), (" Defence " or the " Company "), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it arranges a financing, and its common shares have been upgraded to OTCQB. The Company announces a non-brokered private placement of up to... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), (" Defence " or the " Company "), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it successfully tested a new formulation of... Read More

Vancouver, British Columbia--(Newsfile Corp. - December 11, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) (" Defence " or the " Company "), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that the U.S. FDA has cleared today "Study May Proceed" its Investigational New Drug (IND) application for a Phase I clinical trial of ACCUM-002... Read More

Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - Defence Therapeutics Inc . (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) (" Defence " or the " Company "), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it has successfully submitted on... Read More

Vancouver, British Columbia--(Newsfile Corp. - November 7, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company developing cutting-edge vaccines, therapeutics, and drug delivery technologies against cancer and other diseases, is pleased to announce that the Canadian Intellectual Property Office (CIPO) has issued a Notice of allowance... Read More

Vancouver, British Columbia--(Newsfile Corp. - October 25, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a leading Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the discovery of a novel function for its lead anticancer injectable drug AccuTOX® in the context of... Read More

Vancouver, British Columbia--(Newsfile Corp. - October 18, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that the excitement around AccuTOX TM against cancer continues to develop and expand its applications. The... Read More

Vancouver, British Columbia--(Newsfile Corp. - October 17, 2023) - Defence Therapeutics Inc. (CSE: DTC) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that systemic administration of novel AccuTOX TM -chitosan encapsulated formulation inhibits the growth of pre-established solid lymphoma... Read More

Vancouver, British Columbia--(Newsfile Corp. - October 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a biotechnology company developing various products for the immune-oncology vaccines and drug delivery technologies, is pleased to announce the publication of a peer-reviewed study on the anticancer properties of its unconjugated Accum®, one of Defence's... Read More

Vancouver, British Columbia--(Newsfile Corp. - October 6, 2023) - Defence Therapeutics Inc. ( CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce its participation to the upcoming Festival of Biologics to be held in Basel, Switzerland, October 10-12, 2023.... Read More

Vancouver, British Columbia--(Newsfile Corp. - September 25, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that its encapsulation strategy used to generate Accum®-mRNA lipid nanoparticles (LNPs) results in an... Read More

Vancouver, British Columbia--(Newsfile Corp. - September 22, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce it has entered into a service agreement with Native Ads Inc. ("Native Ads"), pursuant to which Native Ads... Read More

Vancouver, British Columbia--(Newsfile Corp. - September 12, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), one of the leading Canadian biotechnology companies, is pleased to announce its continuation to bringing innovative strategies aimed at targeting various indications related to immune-oncology. Whether using an antibody, cell-based vaccine or small molecule... Read More

Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company ") a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce that Viewpoint, the educational television show distributed nationally and hosted by veteran actor Dennis Quaid, is gearing up... Read More

Vancouver, British Columbia--(Newsfile Corp. - July 18, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company ") is pleased to announce that it has successfully reached the first milestone established in the Collaboration Agreement with Orano Support SAS on behalf of Orano SA ("Orano"), a world-renowned multinational company, headquartered in Chatillon, France, to develop the... Read More

Vancouver, British Columbia--(Newsfile Corp. - July 4, 2023) - Defence Therapeutics Inc. (" Defence " or the " Company ") a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce its collaboration with Viewpoint with Dennis Quaid. This exciting partnership aims to explore breakthroughs in biotechnology and highlight the transformative potential of... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 28, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company ") is a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies. Sitting at the core of its innovative technologies... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 20, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the publication of its new international (PCT) patent application demonstrating the effectiveness of Defence's Accum TM -based... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 16, 2023) - Defence Therapeutics Inc . (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it reached the final stages of its AccuTOX TM Chemistry, Manufacturing and Controls ("CMC") in preparation... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it mandated Transbiotech Biotechnology Research and Transfer Center to initiate testing its cellular... Read More

Vancouver, British Columbia--(Newsfile Corp. - May 26, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that, in addition to the previously announced proceeds of $5,494,375 on March 17, 2023, it has received additional... Read More

Vancouver, British Columbia--(Newsfile Corp. - May 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the successful completion of a pre-clinical study evaluating the therapeutic potency of a second-generation ARM... Read More

Vancouver, British Columbia--(Newsfile Corp. - May 2, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the successful completion of all required pre-clinical efficacy studies regarding its AccuTOX TM program. AccuTOX TM... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 27, 2023) - Defence Therapeutics Inc. (CSE: DTC) (" Defence " or the " Company "), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted registration for its trademark DEFENCE THERAPEUTICS®. This trademark is granted under... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugates ("ADCs"), is pleased to announce the issuance of its US patent no. 11,612,651 by the United States Patent and... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 17, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that it commenced comparing the therapeutic potency of "naked" to Accum TM -linked mRNA in immunocompetent mice.... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that it successfully established a strategy conjugating mRNA molecules to Accum TM . The potency of this... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 28, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it is currently conducting a final pre-clinical study aimed at validating the efficacy of AccuTOX TM... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 17, 2023) - Defence Therapeutics Inc. (CSE: DTC) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that over the course of the last 6 months the Company has received over $5 million in gross proceeds from the exercise of warrants, pursuant... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 14, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), is pleased to announce that it has signed a Collaboration Agreement with Orano Support SAS on behalf of Orano SA ("Orano"), a world-renowned multinational company, headquartered in Chatillon, France, to develop the next generation of radio-immunoconjugates for... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 27, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to update its... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 21, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it signed an agreement with City of Hope National Medical Center and Beckman Research Institute of the... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 3, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its ARM vaccine manufacturing in preparation of its Phase I clinical trial targeting patients with... Read More

Montreal, Quebec--(Newsfile Corp. - February 2, 2023) - In celebration of World Cancer Day, Defence Therapeutics and CQDM are proud to announce the launch of a collaborative research project between Université de Montréal (UdeM), the Lady Davis Institute of the Jewish General Hospital and Defence Therapeutics, a Quebec-based biotechnology company specialized in the development of next-generation vaccines. The funding of this... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 31, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its GLP studies on a new intranasal AccuTOX TM formulation. This milestone is crucial to initiate... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the validation of its ARM vaccine candidate in a melanoma model with a cure rate of 60%. Defence used a variant... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 20, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that Defence will attend, from February 7-10, 2023, the Immuno-Oncology 360º "IO360º" premier meeting across... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 16, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate ("ADC"), is pleased to announce that that the United States Patent and Trademark... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the advancement in the development of its Accum TM -mRNA vaccine program. This R&D program will not only... Read More

Vancouver, British Columbia--(Newsfile Corp. - December 20, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, just completed a pre-clinical study using its intranasal formulation of AccuTOX TM in the context of animals with pre-established... Read More

Vancouver, British Columbia--(Newsfile Corp. - December 15, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is currently working on combining its Accum TM technology with mRNA vaccination as previously announced in press release dated of... Read More

Vancouver, British Columbia--(Newsfile Corp. - December 9, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the appointment of Mr. Kwin Grauer to its board of directors, effective immediately. Mr. Kwin Grauer, CPA, CA,... Read More

Vancouver, British Columbia--(Newsfile Corp. - December 6, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful completion of all GLP studies related to its anti-cancer AccuTOX TM molecule. The Company is... Read More

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the successful completion of its Good Laboratory Practice ("GLP") studies on the AccuVAC-PT007 vaccine candidate specifically designed to target cervical cancer. GLP studies... Read More

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is initiating a new research and development program designed to exploit the Accum TM technology in engineering messenger (m)RNA vaccines targeting cancer. Accum TM is designed for intracellular... Read More

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce a non-brokered private placement of debenture units (the " Units ") at a price of $1,000 per Unit for aggregate gross proceeds of up to $2,355,000 (the " Offering "). Each Unit... Read More

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the start of a pre-clinical program using its novel patent pending technology AccuTOX TM . The novel AccuTOX TM formulation is designed for the treatment of lung cancer including... Read More

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate ("ADC"), is pleased to announce that a notice of allowance has been issued by the Japan Patent Office for its Japanese patent application no.... Read More

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report that Defence's novel vaccine candidate triggers a potent anti-tumoral response capable of curing animals with pre-established lymphoma. Antigen presentation is a crucial step for... Read More

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biotech company actively working on accelerating scientific discoveries and products development against cancer, congratulates the US President Joe Biden for the executive order signed on Monday establishing the Biotechnology and Biomanufacturing initiative to ensure cutting-edge biotechnologies necessary to end... Read More

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the development of a novel anti-cancer cellular vaccine by reprogramming the unconventional suppressive mesenchymal stromal cells (MSCs) into potent antigen presenting cells... Read More

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate ("ADC"), is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted Defence Therapeutics Inc. the U.S. patent no.... Read More

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the discovery of a novel DNA damaging function triggered by one of its lead compounds AccuTOX TM , which effectively elicits cell death in cancer cells. Cancer can be generally... Read More

Defence Therapeutics Inc . (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to provide an update on its ADC programs in development using Defence's Accum TM , including key in vivo studies with worldwide collaborators. The world-renowned Curie Institute, one of... Read More

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report potent pre-clinical results on the use of its Accum TM -linked protein vaccine, AccuVAC-PT007, against cervical cancer. Cervical cancer is a type of cancer affecting the cervix.... Read More

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceuticals company primarily focused on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the development of novel dual-acting Accum TM -linked protein vaccine, AccuVAC-PTE7, dedicated to protect from cervical cancer (prophylactic vaccine) or to treat... Read More

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the development of novel dual-acting Accum TM -linked protein vaccine, AccuVAC-PTE7, dedicated to protect from cervical cancer (prophylactic vaccine) or to treat... Read More

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (" Defence " or the " Company "), a Canadian biopharmaceutical company primarily focused on the development of novel vaccines and drug delivery technologies, is pleased to announced that the United States Patent and Trademark Office (USPTO) has granted patent number US 11,291,717 ('717) covering its breakthrough vaccine platform technology for the... Read More

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF)(" Defence " or the " Company "), a Canadian biotech company actively working on accelerating scientific discoveries and products development against cancer, is pleased to provide an overview of its current research and development progress in various cancer activities. In Q1 of 2022, Defence has signed an agreement with the Advanced Therapies Facilities (ATF)... Read More